Michigan Collaborative for Type 2 Diabetes Training: Novel Medications

Monday, January 10, 2022, 12:00 AM - Monday, January 9, 2023, 11:59 PM

Release Date: January 10, 2022
Expiration Date: January 9, 2023
Estimated Time to Complete:  1 hour, 11 minutes

This recorded training is by invitation only for the members of the Michigan Collaborative for Type 2 Diabetes. See Registration section for instructions on how to get started.

We want to make sure that we answer all your questions about the content of this module. Please email Jackie Rau at [email protected] with any clinical questions that you have from the training and we will ensure that the physician leading the training responds to your questions.

1. Discuss the benefits of SGLT2I and GLP1-RA in treating Type 2 Diabetes.
2. Recall when it is appropriate to prescribe these medications to patients.
3. Recognize potential challenges in prescribing these medications.

There is no fee for this module, however, registration is required.  If you don't already have a profile in the CE portal you will need to create one during the registration process.  Click on the Register tab, complete the prompts in the registration screens and click Finish.  Click on the activity link at the bottom the confirmation window to return to the module (a direct link to the module is also provided in the registration confirmation email).

Instructions for Completion

• After registering, click on the Begin Activity tab and then click Launch Video.
• Upon completion of the video, close that window and click on the Attestation button, complete then click on Show Results.
• Next click on Complete Evaluation, submit and receive credit.

For any reason, if you are not automatically redirected to the evaluation after completing the attestation, click on the orange My CME button, then Evaluations & Certificates to complete the evaluation and claim credit for this module.

Need Assistance? [email protected]

AMA PRA Category 1 Credits™ (1.25 hours), AMA PRA Non-Physician (Attendance) (1.25 hours), Dietetic CPEU (CDR) (1.25 hours), Nursing CE (ANCC) (1.25 hours), Pharmacist CE (ACPE) (1.25 hours), Pharmacy Technician CE (ACPE) (1.25 hours)

In support of improving patient care, this activity has been planned and implemented by Beaumont Health and Michigan Collaborative for Type 2 Diabetes (MCT2D).  Beaumont Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Medicine CME: Beaumont Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing CE: Beaumont Health designates this activity for a maximum of 1.25 ANCC contact hours.  Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy CE: Beaumont Health designates this activity for 1.25 ACPE Universal Activity Number (UAN):  JA4008259-9999-22-037-H01-P; JA4008259-9999-22-037-H01-T.  Pharmacists and pharmacy technicians should claim only the credit commensurate with the extent of their participation in the activity.  Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion.  Per ACPE rules, Beaumont Health does not have access nor the ability to upload credits requested after the evaluation closes.  It is the responsibility of the pharmacist and pharmacy technician to provide the correct NABP ID and DOB to receive credit.

Dietetic CPEU:

Financial disclosures can be viewed in the Faculty tab.

References:

1. Gay, H., Yu, J., Petito, L., Isakova, T., Srivastava, A., Khan, S., Persell, S. D., Linder, J., Mutharasan, R. K., Huffman, M. D., Shah, S. J., Yancy, C. W., & Ahmad, F. S. (2020). Abstract 14678: Prevalence of SGLT2 inhibitor and GLP-1 receptor agonist prescriptions in patients with comorbid diabetes and cardiovascular disease in an Integrated Academic Health System. Circulation, 142(Suppl_3). https://doi.org/10.1161/circ.142.suppl_3.14678.

2. Artigas CF, Stokes V, Tan GD, Theodorakis MJ. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice. Expert Opin Pharmacother. 2015;16(10):1417-1421. doi:10.1517/14656566.2015.1052740.

3. Brady SM, Kane MP, Busch RS. GLP-1 Agonist Use in a Patient with an Explainable Cause of Pancreatitis. AACE Clinical Case Reports, Volume 2, Issue 2, 2016, Pages e82-e85, https://doi.org/10.4158/EP15658.CR.

4. Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 2021;44(1):290-296. doi:10.2337/dc20-1815.

5. Diabetes Technology: Standards of Medical Care in Diabetes—2021. American Diabetes Association. Diabetes Care Jan 2021, 44 (Supplement 1) S85-S99; DOI: 10.2337/dc21-S007.

6. Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. Ann Pharmacother. 2021 Apr;55(4):543-548. doi: 10.1177/1060028020951928. Epub 2020 Aug 18. PMID: 32808541.

7. Luo J, Feldman R, Rothenberger SD, Hernandez I, Gellad WF. Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program. JAMA Netw Open. 2020;3(10):e2020969. doi:10.1001/jamanetworkopen.2020.20969.

Unapproved Use: It is the policy of Beaumont Health to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this accredited CE activity may reference off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Mitigation of Relevant Financial Relationships

Beaumont Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Financial disclosures for speakers and planners are listed below.